X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the licensing agreement, Ipsen has exclusive worldwide rights to develop and commercialize STRO-003, an ROR1 inhibitor currently undergoing clinical evaluation for the treatment of neoplasms.
Lead Product(s): STRO-003
Therapeutic Area: Oncology Product Name: STRO-003
Highest Development Status: PreclinicalProduct Type: Large molecule
Recipient: Sutro Biopharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement April 02, 2024
Details:
Ipsen acquired exclusive commercialization rights for the current and potential future Onivyde, a unique encapsulation formulation of irinotecan in a long-circulating liposomal, as a first-line treatment of metastatic adenocarcinoma on the pancreas in the US.
Lead Product(s): Irinotecan Hydrochloride,Fluorouracil,Calcium Folinate
Therapeutic Area: Oncology Product Name: Onivyde
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Merrimack Pharmaceuticals
Deal Size: $1,025.0 million Upfront Cash: $575.0 million
Deal Type: Acquisition March 27, 2024
Details:
Onivyde (irinotecan), liposomal injection is a small molecule drug that blocks an enzyme called topoisomerase I. It is being developed for the treatment of metastatic pancreatic adenocarcinoma.
Lead Product(s): Irinotecan Hydrochloride,Fluorouracil,Calcium Folinate
Therapeutic Area: Oncology Product Name: Onivyde
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 13, 2024
Details:
GFT505 (elafibranor) is a novel, oral, once-daily, dual peroxisome activated receptor (PPAR) alpha/delta agonist, currently under investigation as a treatment for patients with primary biliary cholangitis.
Lead Product(s): Elafibranor
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: GFT505
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 07, 2023
Details:
Bylvay (odevixibat) is a potent, once-daily, non-systemic IBATi that acts locally in the small intestine and has minimal systemic exposure. It is approved in the U.S. for the treatment of pruritus due to Progressive Familial Intrahepatic Cholestasis.
Lead Product(s): Odevixibat
Therapeutic Area: Genetic Disease Product Name: Bylvay
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 13, 2023
Details:
Bylvay (odevixibat) is a potent, once-daily, non-systemic IBATi that acts locally in the small intestine and has minimal systemic exposure. It is approved in the U.S. for the treatment of Alagille syndrome.
Lead Product(s): Odevixibat
Therapeutic Area: Genetic Disease Product Name: Bylvay
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 23, 2023
Details:
QM-1114 (botulinum toxin type A) liquid is a neuromodulator with a 900 kDa protein complex derived from neurotoxins produced by Clostridium botulinum. It is being investigated for movement disorders such as cervical dystonia.
Lead Product(s): Botulinum toxin type A
Therapeutic Area: Dermatology Product Name: QM1114
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 03, 2023
Details:
Under the agreement, IRLAB secured full ownership rights for the now Phase III-ready IRL790 (mesdopetam), a dopamine D3 receptor antagonist, in development as a treatment of Parkinson's disease levodopa-induced dyskinesias.
Lead Product(s): Mesdopetam
Therapeutic Area: Neurology Product Name: IRL790
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: IRLAB
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement August 21, 2023
Details:
Cabometyx (Cabozantinib) tablet is a multiple receptor tyrosine kinases inhibitor, being investigated in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer.
Lead Product(s): Cabozantinib S-Malate,Atezolizumab
Therapeutic Area: Oncology Product Name: Cabometyx
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Exelixis
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 21, 2023
Details:
Under the termination, Ipsen will retain all rights and obligations related to its early-stage R&D neurotoxin pipeline, including the development of IPN10200 (abobotulinumtoxinA), for the treatment of upper facial lines and muscle spasticity.
Lead Product(s): Botulinum toxin type A
Therapeutic Area: Dermatology Product Name: IPN10200
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Galderma
Deal Size: $41.1 million Upfront Cash: $13.7 million
Deal Type: Termination July 27, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
